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ABSTRACT: Bacterial infections resulting from nonsurgical
traumatic wounds can be life threatening, especially those
caused by multidrug-resistant (MDR) bacteria with limited
therapeutic options. The antimicrobial activity of polymyxin B
(1) and curcumin (2) alone and in combination was
determined versus MDR bacterial isolates associated with
traumatic wound infections. Cytotoxicity assays for 1 and 2
were undertaken in keratinocyte cell lines. Minimum inhibitory
concentrations of 1 were signiﬁcantly reduced in the presence
of 2 (3- to 10-fold reduction), with synergy observed. Time−
kill assays showed the combinations produced bactericidal activity. Cytotoxicity assays indicate the toxicity of 2 was reduced in
the presence of 1.
Complicated bacterial infections resulting from nonsurgicaltraumatic wounds and/or burns arise rapidly due to the
loss/penetration of the natural barrier, the skin, and can be life
threatening. These infections are commonly caused by bacteria
such as Staphylococcus aureus, Streptococcus pyogenes, vancomy-
cin-resistant Enterococci, Pseudomonas aeruginosa, and Escher-
ichia coli.1 An increasing number of these infections are caused
by multidrug-resistant (MDR) strains, which can lead to longer
hospital stays, increased ﬁnancial burden, and higher rates of
morbidity and mortality.2 Multidrug resistance has led to the
use of “last line” antibiotics such as carbapenems or older
antibiotics such as polymyxins, which can produce renal
toxicity.3 Increased resistance to carbapenems is also increasing
due to emergence and rapid dissemination of carbapenemases-
producing strains.4 Several studies report limited therapeutic
options to treat MDR bacterial infections.5−7 Physicians often
use unorthodox antibiotic combinations to increase the eﬃcacy
of treatment.8
Like colistin, 1 is a cyclic polypeptide antibiotic, with
antibacterial activity against Gram-negative bacteria such as
Acinetobacter baumannii, P. aeruginosa, E. coli, and Klebsiella
pneumoniae and has been used topically for many years for the
treatment of skin infections. In 1956, it was used in
combination with B-bacitracin-neomycin as an eﬀective
antimicrobial ointment against a variety of micro-organisms.9
1 has also been used in selective decontamination regimes to
suppress the growth of Enterobacteriaceae.10 Like colistin
(polymyxin E), 1 has seen increased use to treat Gram-negative
bacterial infections, due to the emergence of resistance to
antibiotics such as carbapenems.11 However, increased
resistance to polymyxins has emerged,12 which is likely due
to their revival in clinical settings and continued agricultural
use. The recent discovery of the mobile colistin resistance gene
(MCR-1) in humans and animals has increased the concern of
the future eﬃcacy of polymyxins.13
One possible solution would be to use 1 in combination with
the phenolic compound curcumin (2). 2 is a major component
of the spice turmeric from the plant Curcuma longa Linn. and
has been used as a natural antimicrobial in Asia for many years.
Previous work has shown 2 to be an eﬀective antimicrobial
agent against various human pathogens.14,15 It has also been
previously recognized for its ability to prevent oxidative stress
in skin cells and for its potential to aid in wound healing.16
Moreover, studies have reported the ability of 2 to reduce
epidermal tumor size and formation in mice.17 Combinations of
2 with other antimicrobials has also been shown to be eﬀective
against MDR bacteria such as A. baumannii.18 Novel
combination therapy has recently been proposed for the
treatment of complicated skin infections caused by multidrug-
resistant bacteria using antibiotics or antibiotics in combination
with natural compounds.19 Using combination therapy, the
eﬃcacy of drugs such as the polymyxins could be preserved
and/or extended.
Here we aimed to determine the in vitro activity of
polymyxin B and curcumin, alone and in combination, against
antibiotic-susceptible and -resistant Gram-positive (Enterococci,
S. aureus, and Streptococci) and Gram-negative (A. baumannii, E.
coli, P. aeruginosa, and S. maltophilia) bacterial isolates
associated with traumatic wound infections.
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1 produced good antibacterial activity against Gram-negative
strains with minimum inhibitory concentrations (MICs) of
0.096−6.1 μM (Table 1). Antimicrobial activity was also
demonstrated against isolates of S. pyogenes with MICs of 3−
12.3 μM. As expected, very high MICs of 174−347 μM for 1
were observed versus S. aureus and Enterococcus spp. and would
normally be classed as unsusceptible. Compound 2 produced
weak antibacterial activity with high MICs (174−2780 μM) in
Table 1. Minimum Inhibitory Concentrations (MICs) of Polymyxin B (PB) and Curcumin (CCM) Alone or in Combination
and Fractional Inhibitory Concentration Indices (FICIs) for Important Potential Pathogens of Traumatic Wounds Expressing a
Variety of Antimicrobial Resistance Mechanismsa
MICs (μM) MICs in combination
isolate characteristics 1 2 1 + 2 2 + 1 FICI
E. faecium OEF42 VRE (vanA) 98 350 3.1 22 0.094
E. faecium OEF65 VRE (vanA/B) 49 174 1.5 43 0.281
E. faecalis ATCC 29212 type strain 98 350 0.096 87 0.251
S. aureus Mu50 VISA (vraSR) 98 2780 1.5 43 0.047
S. aureus ATCC 25923 type strain 98 2780 6.1 87 0.156
S. aureus NCTC 12493 MRSA (mecA) 98 2780 0.79 43 0.031
S. pyogenes SPY1 wound isolate 6.1 350 0.19 43 0.094
S. pyogenes SPY2 wound isolate 12.3 174 0.79 22 0.188
S. pyogenes SPY3 wound isolate 3.1 174 0.79 43 0.500
E. coli EC2 CTX-M-15 0.096 2780 0.024 43 0.266
E. coli EC204 NDM-1 0.096 2780 0.024 174 0.313
E. coli NCTC 12241 type strain 0.048 2780 0.024 43 0.520
A. baumannii AB12 OXA-23 0.19 2780 0.024 87 0.156
A. baumannii AB14 OXA-23 clone 1 0.096 1390 0.024 174 0.375
A. baumannii AB16 OXA-23 clone 2 0.19 2780 0.012 22 0.068
A. baumannii NCTC 19606 type strain 0.19 2780 0.012 22 0.068
P. aeruginosa PA01 reference strain 0.78 1390 0.012 43 0.031
P. aeruginosa PA14 reference strain 0.78 1390 0.012 22 0.023
P. aeruginosa PA30 VIM-2 0.39 2780 0.19 174 0.563
P. aeruginosa ATCC 27853 type strain 0.39 1390 0.006 174 0.079
S. maltophilia SMS01 L1, TEM 6.1 2780 0.024 22 0.012
S. maltophilia SMB07 L1, TEM 1.5 2780 0.0313 22 0.023
S. maltophilia NCTC 10258 type strain 1.5 2780 0.008 22 0.012
aMRSA, methicillin-resistant Staphylococcus aureus; VISA, vancomycin-intermediate resistant S. aureus; VRE, vancomycin-resistant Enterococcus;
PA14, common, highly virulent clone. All S. pyogenes strains are antibiotic-susceptible wound isolates.
Figure 1. Time−kill curves of polymyxin B (PB) and curcumin (CCM) alone and in combination versus (a) A. baumannii (ATCC 19606), (b) S.
maltophilia (NCTC 10258), (c) P. aeruginosa (ATCC 27853), and (d) Methicillin-resistant S. aureus (NCTC 12493).
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all clinical isolates and type strains. When added in
combination, 1 and 2 produced increased antibacterial activity
with MICs signiﬁcantly reduced (3- to 10-fold reduction, p <
0.005). The fractional inhibitory concentration indices (FICIs)
calculated suggest that synergy was produced in 21/23 strains
(FICI ≤ 0.5). In 2/23 strains an additive eﬀect was produced
(FICI > 0.5−4.0).
Time−kill results demonstrated that 2 was only eﬀective
against P. aeruginosa (ATCC 27853), with a 2 log reduction in
colony-forming units (CFU)/mL over 24 h (Figure 1d).
Regrowth was observed for the three other strains over 24 h,
indicating that, alone, 2 was ineﬀective as an antibacterial agent.
1 was eﬀective in reducing the CFU/mL in the Gram-negative
isolates by 2 logs at 6 h. Regrowth was observed at 24 h in S.
maltophilia (NCTC 10258). As expected 1 alone had no eﬀect
against MRSA (NCTC 12493), with growth almost equal to
that of the no-drug control. However, the combination of 2
with 1 showed signiﬁcant antibacterial activity, and complete
cell death was observed in all strains between 4 and 6 h (Figure
1). The combination was clearly bactericidal, and signiﬁcant
synergy was produced, indicated by a >3 log CFU/mL
diﬀerence between the agents used in combination versus
alone.18
The data presented here with the exception of P. aeruginosa
agree with previous results, whereby 2 alone showed no
antibacterial activity over 24 h, in time−kill assays.18 This could
be due to the insolubility of 2 or the inability of the compound
to pass through the outer cell membrane/cell wall to reach its
target.
Previous studies performed with B. subtilis indicate that the
mode of antibacterial action of 2 involves the disruption of FtsZ
protoﬁlament activity, previously shown to be critical in
bacterial cytokinesis.20 This disruption inhibits bacterial cell
proliferation by inhibiting the assembly of the Z ring. 2 has
been shown to inhibit the bacterial surface protein sortase A,
preventing cell adhesion to ﬁbronectin, leading to bacterial cell
death in S. aureus.21 The mechanism through which 2
nanoparticles (NPs) are believed to generate antibacterial
action is by attaching to the bacterial cell wall, leading to
disruption and eventual diﬀusion of NPs within the cell,
resulting in further disrupting of biochemical processes.22
The addition of 1, a known membrane permeabilizer, may
result in greater quantities of 2 entering Gram-negative
bacterial cells, leading to increased toxicity. However, increased
toxicity of the 1/2 combination was also observed against
Gram-positive bacteria. This in part could be due to the ability
of 2 to cause bacterial cell wall damage,23 allowing 1 to disrupt
the physical integrity of phospholipid bilayer of the inner
membrane.24
Cytotoxicity of 1 alone was very low (2% ± 0.01 percentage
point [pp] at 6.1 μM), whereas 2 showed 34% (±2 pp) toxicity
at concentrations of 174 μM (Figure 2). However, the
cytotoxicity of 2 versus HaCaT keratinocyte cells was reduced
signiﬁcantly (22% ± 3 pp, p = <0.01) when used in
combination with 1, at concentrations of 43.4:1.5 μM.
Although cytotoxicity in combination is reduced in keratino-
cytes, it is increased versus bacterial cells, an important
prerequisite for a topical therapy.
Although previous studies have also shown that 2 induces
apoptosis in epidermal cells at 12.5−25 μM,25 other studies
have demonstrated that greater concentrations of 2 are required
to induce in vitro cytotoxicity, with ≥25 μM 2 required for a
50% reduction in HaCaT (keratinocyte) cells and ≥50 μM
required for a 50% reduction in melanocytes.26 These would be
equal or higher than the concentrations of 2 required in
combination to inhibit the growth of 70% of the isolates tested
in this study. Although 2 exposure in vitro caused cytotoxicity
in HaCaT keratinocytes in this study, previous topical
applications have shown no skin irritation in a live rat
model,27 indicating whole skin models have increased resistance
to toxicity from 2.
Data from phase I clinical trials have also shown that 2 is not
toxic to humans up to concentrations of 21.72 mM, when taken
orally.28,29 A randomized, double-blind, placebo-controlled
clinical trial of the eﬀectiveness of 2 to treat mastitis also
found no skin toxicity at 8 h doses of 5.49 mM applications.30
The trial also observed signiﬁcant reduction in inﬂammation
and pain, indicating topical therapies of 2 were successful in
treating mastitis.
Previously research has suggested that in vitro deposition of
2 on the skin was low 24 h after topical application,31 which
could be due to solubility issues of 2. It was suggested that
enhancers were required for eﬀective topical applications of 2, if
Figure 2. Cytotoxicity via lactase dehydrogenase assay of (a)
polymyxin B (1), (b) curcumin (2), and (c) combinations of both
agents in HaCaT cells ± standard deviation, with the combination
(43:1.5 μM) showing less toxicity than 2 alone (p = <0.01).
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the desired therapeutic eﬀects were to be achieved. Other
natural compounds such as terpenes or polyphenols such as
epigallocatechin gallate (EGCG) could be used to aid 2
penetration into the skin.31 Combinations of 2 and EGCG have
previously shown potential as an antimicrobial therapy and
could be used as a third agent with 1 and 2.18 Another option
would be to use 2 nanoparticles in the formulation. 2
nanoparticles have previously shown to have enhanced
antibacterial activity, water solubility, and a reduced risk of
cytotoxicity in human cells.22
In conclusion, antimicrobial synergy produced between 1
and 2 suggests that combinations of the two compounds could
be used clinically for topical therapy to treat or prevent
traumatic wound infections of the skin. The addition of 2 to
current treatment containing 1 would not only increase the
spectrum of activity to include Gram-positive bacteria but also
combat those isolates resistant to 1 alone. The use of the
combination may also reduce the emergence of resistant
isolates during treatments, due to the multiple antimicrobial
targets of duel drug therapy and ease the selective pressure
produced by broad-spectrum antibiotics. Further work should
focus on triple combinations with enhancers, such as EGCG, to
increase the potency of the combinations’ antimicrobial action.
■ EXPERIMENTAL SECTION
Bacterial Strains and Media. Bacterial-type strains were
purchased from the National Collection of Type Cultures (NCTC),
Public Health England (Colindale, UK). The S. aureus (VISA) stain
was obtained from the Network for Antimicrobial Resistance in S.
aureus (NARSA, USA). Clinical isolates were sourced from Barts
Health NHS Trust or the existing collection held at Queen Mary
University London. Identiﬁcation and routine antibiograms for clinical
isolates were performed according to the laboratories accredited
standard protocol (CPA). Curcumin powder (≥95% purity, cat. no. sc
294110, lot no. 191793-67) was purchased from Santa Cruz
Biotechnology Inc. (Heidelberg, Germany). Polymyxin B sulfate
powder was purchased from VWR International LTD (Leighton
Buzzard, UK). All media was purchased from Thermo Fisher Inc.
(Basingstoke, UK) and autoclaved prior to use.
Antimicrobial Susceptibility Assays. Minimum inhibitory
concentrations of 1 and 2 were determined alone and in combination
against 23 clinical isolates and type strains of Gram-negative and
Gram-positive bacteria, related to traumatic wound infections, with
varying degrees of antibiotic resistance (Table 1). Checkerboard
assays, performed in separate 96-well microtiter plates, were inoculated
with IsoSensitest broth containing 106 colony-forming units/mL of
each isolate. Checkerboard assays were read after 24 h of incubation at
37 °C. Fractional inhibitory concentration indices were calculated
based on the method previously described,32 whereby FICa = MIC of
compound a + compound b/MIC of compound a, FICb = MIC of
compound b + compound a/MIC of compound b, and FICs = FICa +
FICb. FICIs ≤ 0.5 were recorded as synergistic, values > 0.5−4.0 were
recorded as an additive eﬀect, and a value > 0.4 was considered
antagonistic. Where the MIC was not attained, the dilution above the
maximum dose was used to calculate the FICI. All experiments were
carried out in triplicate, and results are presented as mean values.
Time−kill assays were undertaken to determine the antibacterial
activity of mono- and combination therapies against A. baumannii
(ATCC 19606), P. aeruginosa (ATCC 27853), methicillin-resistant S.
aureus (NCTC 12493), and Stenotrophomonas maltophilia (NCTC
10258) over 24 h. A 1/1000 dilution of an overnight culture (16 h in
Mueller-Hinton 2 broth) (approximately 106 CFU/mL) was used as
the starting inoculum (10 mL in universal tubes), before the addition
of 1 (×1 MIC), 2 (×1 MIC), or combinations (×1 MIC 1:×0.5 MIC
2). Cultures were incubated at 37 °C under continuous agitation for
24 h. At time intervals of 0, 2, 4, 6, and 24 h postinoculation, 100 μL
samples were collected, serially diluted, and plated onto IsoSensitest
agar. Inoculated plates were incubated at 37 °C for 20 h before
colonies were counted. Time−kill curves (CFU/mL vs time) were
plotted using GraphPad software. Synergy was deﬁned as bactericidal
activity (≥2 log10 diﬀerence in CFU/mL) of the combination
compared to the single agent after 24 h of incubation.
Skin Cell Toxicity Assays. Cytotoxicity assays, versus human skin
cells, were undertaken to assess the potential of 1/2 combinations as
topical treatments for skin infections. Skin cell toxicity assays were
performed using the CytoTox 96 nonradioactive cytotoxicity assay
(Promega Co., Southampton, UK) to monitor lactate dehydrogenase
(LDH), an indicator of percent cell toxicity. Human epidermal
keratinocytes (HaCaT) were plated at 10 000 cells per well in 96-well
plates and grown until subconﬂuent, in phenol-free Dulbecco’s
modiﬁed Eagle’s medium supplemented with 2.5% (v/v) fetal bovine
serum (FBS) and 2 mM L-glutamine. Double dilutions of 1, 2, and
combinations of both agents were performed in vertical wells on a 96-
well microtiter plate before being transferred to a 96-well microtiter
plate with half the plate containing human keratinocytes and the
second half containing just 2% FBS phenol-free media. Final
concentrations were 25−0 μM for 1 and 174−0 μM for 2.
Concentrations of the combinations were the sum of 1 and 2 for
monotherapy (2:1). DMSO, phosphate-buﬀered saline (PBS), and
LDH positive controls were added to the plate. Microtiter plates were
incubated at 37 °C for 4 h. After this time cells were washed in PBS.
To each well was added 10 μL of lysis solution, and the mixture
incubated at 37 °C for 40 min before centrifugation at 250g for 4 min.
From each well, 50 μL of the supernatant was added to a sterile ﬂat-
bottom enzymatic assay plate, before 50 μL of reconstituted substrate
mix was added to each well and incubated at room temperature,
protected from light, for 30 min. After incubation, 50 μL of stop
solution was added to each well, and absorbance was recorded using a
plate reader (Wallac 1420 VICOTOR2, PerkinElmer, USA) set at 490
nm. All assays were performed in duplicate. Percentage cytotoxicity
was calculated, and graphs were plotted using Excel 2013.
Statistical Analysis. Student t tests were performed using Excel
2013, to check for any signiﬁcant diﬀerences between data sets.
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